Close Menu

hereditary disease

The panels yielded a diagnosis for 43 percent of more than 2,300 patients, at a cost between $75 and $150 per panel.

The company recently launched a next-gen sequencing newborn screening panel, targeting 89 genes that have been linked to more than 60 metabolic conditions.

The privately-held German firm also plans to offer genetic tumor profiling and noninvasive prenatal testing.

The retrospective study, by researchers at Children's Mercy Kansas City, suggests the STAT-seq test has clinical utility in some patients.

The NYGC is currently preparing to submit a number of additional clinical tests to the state including assays for cancer and constitutional disorders.

The lab has also switched its gene panels from the Illumina HiSeq to the MiSeq platform.

The company has raised a total of $75 million in venture capital to date.

Using arrays and exome sequencing, the study aims to diagnoses children with previously undiagnosed developmental disorders.

Invitae has received accreditation for its laboratory from the College of American Pathologists as well as coverage eligibility from Blue Shield of California and the Centers for Medicare and Medicaid Services.

The American College of Medical Genetics & Genomics updated its recommendations for the analysis & reporting of secondary findings from clinical genome-scale sequencing & released results of a 2013 about its initial recommendations from 2013.

Pages

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.